Principles of safety pharmacology

British Journal of Pharmacology

Volumn 154, Issue 7, 2008, Pages 1382-1399

  Pugsley, M K ^a   Authier, S ^b   Curtis, M J ^c  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b LAB Research Inc   (Canada)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Drug discovery; hERG; Safety Pharmacology; Torsades de Pointes; Toxicology; TRIaD

Indexed keywords

ANTIBODY; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; BIOLOGICAL MARKER; CIMETIDINE; CLEMASTINE; CLEMASTINE FUMARATE; DIPHENHYDRAMINE; IBUPROFEN; MACROLIDE; POTASSIUM CHANNEL HERG; TERFENADINE;

ACCREDITATION; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CLINICAL STUDY; DRUG FATALITY; DRUG INDUSTRY; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; GOOD LABORATORY PRACTICE; HUMAN; METHODOLOGY; MOLECULAR SIZE; NONHUMAN; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATORY SYSTEM; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SAFETY PHARMACOLOGY; STATISTICAL ANALYSIS; TORSADE DES POINTES; TOXICOLOGY; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION;

ANIMALS; DRUG AND NARCOTIC CONTROL; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 48149103387     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.280     Document Type: Review

References (93)

1. Ando K, Hombo T, Kanno A, Ikeda H, Imaizumi M, Shimizu N et al. (2005). QT PRODACT: in vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. J Pharmacol Sci 99: 487-500.
2. Ator NA, Griffiths RR (2003). Principles of drug abuse liability assessment in laboratory animals. Drug Alc Dep 70: S55-S72.
3. Authier S, Legaspi M, Gauvin D, Chaurand F, Fournier S, Troncy E (2008). Validation of respiratory Safety Pharmacology models: conscious and anesthetized beagle dogs. J Pharmacol Toxicol Methods 57: 52-60.
4. Authier S, Tanguay JF, Gauvin D, Fruscia RD, Troncy E (2007). A cardiovascular monitoring system used in conscious cynomolgus monkeys for regulatory Safety Pharmacology. Part 2: pharmacological validation. J Pharmacol Toxicol Methods 56: 122-130.
5. Balser RL, Bigelow GE (2003). Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alc Dep 70: S13-S40.
6. Bass AS, Kinter L, Williams P (2004a). Origins, practices and future of safety pharmacology. J Pharmacol Toxicol Methods 49: 145-151.
7. Bass AS, Vargas HM, Kinter LB (2004b). Introduction to Nonclinical safety pharmacology and the safety pharmacology society. J Pharmacol Toxicol Methods 49: 141-144.
8. Bellemin-Baurreau J, Poizot A, Hicks PE, Armstrong JM (1994). An in vitro method for the evaluation of antiarrhythmic and anti-ischemic agents by using programmed electrical stimulation of rabbit heart. J Pharmacol Toxicol Methods 31: 31-40.
9. Billman GE (2006). A comprehensive review and analysis of 25 years of data from an in vivo canine model of sudden cardiac death: implications for future anti-arrhythmic drug development. Pharmacol Ther 111: 808-835.
10. Botting JA, Curtis MJ, Walker MJA (1985). Arrhythmias associated with myocardial ischaemia and infarction. Mol Aspects Med 8: 307-422.
11. Chaves AA, Keller WJ, O'Sullivan S, Williams MA, Fitzgerald LE, McPherson HE et al. (2006). Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation. J Pharmacol Toxicol Methods 54: 150-158.
12. Chaves AA, Zingaro GJ, Yordy MA, Bustard KA, O'Sullivan S, Galijatovic-Idrizbegovic A et al. (2007). A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. J Pharmacol Toxicol Methods 56: 103-114.
13. Chung PH, Pugsley MK, Walker MJA (1993). Arrhythmia models in the rat. J Pharmacol Toxicol Methods. 29: 179-184.
14. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski Dnguyen L et al. (2007). Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370: 2011-2019.
15. Curtis MJ (1998). Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation. Cardiovasc Res 39: 194-215.
16. Darpo B (2001). Spectrum of drugs prolonging QT interval and the incidence of Torsades de pointes. Eur Heart J 3 (Suppl. K): K70-K80.
17. Darpo B, Nebout T, Sager PT (2006). Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol 46: 498-507.
18. Demetri GD, van Oosteroum AT, Garrett CR, Blackstein ME, Shah MH, Verweij J et al. (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 368: 1329-1338.
19. Durmuller N, Guillaume P, Lacroix P, Porsolt RD, Moser P (2007). The use of the dog electroencephalogram (EEG) in Safety Pharmacology to evaluate proconvulsant risk. J Pharmacol Toxicol Methods 56: 234-238.
20. EMEA/CPMP/SWP (2006). Guideline on the non-clinical investigation of the dependence potential of medicinal products. EMEA/CPMP/SWP/94227, 23 March 2006.
21. Eschalier A, Lavarenne J, Burtin C, Renoux M, Chapuy E, Rodriguez M (1988). Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 21: 246-250.
22. Farkas A, Curtis MJ (2002). Limited effectiveness of clinically-relevant concentrations of Class I antiarrhythmics in isolated perfused rat hearts. J Cardiovasc Pharmacol 39: 412-424.
23. Feltenstein MW, See RE (2008). The neurocircuitry of addiction. Br J Pharmacol advance online publication 3 March; doi: 10.1038/bjp.2008.51.
24. Friedrichs GS, Patmore L, Bass AS (2005). Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies. J Pharmacol Toxicol Methods 52: 6-11.
25. Garber K (2006). The second wave in kinase cancer drugs. Nature Biotechnol 24: 127-130.
26. Hamlin RL (2007). Animal models of ventricular arrhythmias. Pharmacol Ther 113: 276-295.
27. Hamlin RL, Cruze CA, Mittelstadt SW, Kijtawornrat A, Keene BW, Roche BM et al. (2004). Sensitivity and specificity of isolated perfused guinea pig heart to test for drug-induced lengthening of QTc. J Pharmacol Toxicol Methods 49: 15-23.
28. Hauser DS, Stade M, Schmidt A, Hanauer G (2005). Cardiovascular parameters in anaesthetized guinea pigs: a Safety Pharmacology screening model. J Pharmacol Toxicol Methods 52: 106-114.
29. Health Canada (2006). Draft Guidance for Industry: clinical assessment of abuse liability for drugs with central nervous system activity. Health Canada Publications 02 January 2006.
30. Hondeghem LM, Lu HR, van RossemK, De Clerck F (2003). Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol 14: 287-294.
31. Irwin S (1968). Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 13: 222-257.
32. Johanson CE (1990). The evaluation of the abuse liability of drugs. Drug Saf 5: 46-57.
33. Johnston KM, MacLeod BA, Walker MJA (1983). Responses to ligation of a coronary artery in conscious rats and the actions of antiarrhythmics. Can J Physiol Pharmacol 61: 1340-1353.
34. June RA, Nasr I (1997). Torsades de pointes with terfenadine ingestion. Am J Emerg Med 15: 542-543.
35. Kagstrom J, Sjogren EL, Ericson AC (2007). Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs. J Pharmacol Toxicol Methods 56: 186-193.
36. Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC (2006). Molecular determinants of HERG channel block. Mol Pharmacol 69: 1709-1716.
37. Kerkala R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al. (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12: 908-916.
38. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C et al. (2008). Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer; e-pub ahead of print, doi 10.1002/cncr.23460.
39. Kemp JP (1992). Antihistamines - is there anything safe to prescribe? Ann Allergy 69: 276-280.
40. Kien ND, Quam DD, Reitan JA, White DA (1992). Mechanism of hypotension following rapid infusion of protamine sulfate in anesthetized dogs. J Cardiothorac Vasc Anesth 6: 143-147.
41. Lawrence CL, Bridgland-Taylor MH, Pollard CE, Hammond TG, Valentin JP (2006). A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. Br J Pharmacol 149: 845-860.
42. Lin C, Ke X, Cvetanovic I, Ranade V, Somberg J (2005). The influence of extracellular acidosis on the effect of IKr blockers. J Cardiovasc Pharmacol Ther 10: 67-76.
43. Lindgren S, Bass AS, Briscoe R, Bruse K, Friedrichs GS, Kallman M-J et al. (2008). Benchmarking Safety Pharmacology Regulatory Packages and Best Practice. J Pharmacol Toxicol Methods.
44. Liu T, Brown BS, Wu Y, Antzelevitch C, Kowey PR, Yan GX (2006). Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 3: 948-956.
45. Luft J, Bode G (2002). Integration of safety pharmacology endpoints into toxicology studies. Fundam Clin Pharmacol 16: 91-103.
46. Marafino BJ, Pugsley MK (2003). Biotechnology-derived therapeutics in cardiovascular disease. Cardiovasc. Toxicol 3: 5-12.
47. Masini E, Planchenault J, Pezziardi F, Gautier P, Gagnol JP (1985). Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions 16: 470-477.
48. Mattsson JL, Spencer PJ, Albee RR (1996). A performance standard for clinical and functional observational battery examinations of rats. J Am Coll Toxicol 15: 239.
49. Miyazaki H, Watanabe H, Kitayama T, Nishida M, Nishi Y, Sekiya K et al. (2005). QT PRODACT: sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation. J Pharmacol Sci 99: 523-529.
50. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena Jr LR (1990). Torsades de pointes occurring in association with terfenadine use. JAMA 264: 2788-2790.
51. Morrison AR, Ator NA, Nakamura RK (eds). (2002). Report of a National Institutes of Health Workshop. NIH Publication No. 02-5083, US Government Printing Office: Washington DC.
52. to are present in the ventricle of Gottingen minipig heart. J. Pharmacol Toxicol Methods, in press.
53. Morganroth J, Gussack I, (eds). (2005). Cardiac Safety of Noncardiac Drugs: Practical Guidelines for Clinical Research and Drug Development. Humana Press: New Jersey.
54. Morton DB, Hawkins P, Bevan R, Heath K, Kirkwood J et al. (2003). Refinements in telemetry procedures. Seventh report of the BVAAWF/FRAME/RSPCA/ UFAW Joint Working Group on Refinement, Part A. Lab Animal 37: 261-299..
55. Morris LS, Carlson A (1998). Protecting patients from harm: Terfenadine and potential drug therapy interactions. Drug Info J 32: 339-345.
56. Moscardo E, Maurin A, Dorigatti R, Champeroux P, Richard S. (2007). An optimised methodology for the neurobehavioural assessment in rodents. J Pharmacol Toxicol Methods 56: 239-255.
57. Murphy DJ, Joran ME (1992). Respiratory and cardiovascular changes associated with toxic doses of a peptide antagonist of vasopressin in the rat. Fundam Appl Toxicol 18: 307-313.
58. Murphy SM, Palmer M, Poole MF, Padegimas L, Hunady K, Danzig J et al. (2006). Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. J Pharmacol Toxicol Methods 54: 42-55.
59. National Cancer Institute (2007). NCI Fact Book. Office of Budget and Finance, National Cancer Institute: Bethesda, MD, http://obf.cancer.gov.
60. Ollerstam A, Visser SA, Duker G, Forsberg T, Persson AH, Nilsson LB et al. (2007). Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. J Pharmacol Toxicol Methods 56: 131-144.
61. Omata T, Kasai C, Hashimoto M, Hombo T, Yamamoto K (2005). QT PRODACT: comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. J Pharmacol Sci 99: 531-541.
62. Patel SP, Campbell DL (2005). Transient outward potassium current, 'Ito', phenotypes in the mammalian left ventricle: underlying molecular, cellular and biophysical mechanisms. J Physiol 569: 7-39.
63. Pratt CM, Camm AJ, Cooper W, Friedman PL, MacNeil DJ, Moulton KM et al. (1998). Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? Am J Cardiol 81: 869-876.
64. Pratt CM, Hertz RP, Ellis BE, Crowell SP, Louv W, Moye L. (1994). Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol 73: 34652.
65. Pugsley MK (2004). Safety pharmacology matures into a unique pharmacological discipline. J Pharmacol Toxicol Meth 49: 137-139.
66. Redfern WS, Strang I, Storey S, Hays C, Barnard C, Lawton K et al. (2005). Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds. J Pharmacol Toxicol Meth 52: 77-82.
67. Rees SA, Curtis MJ (1996). Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias? Pharmacol Ther 69: 199-217.
68. Rosen MR (1996). Of oocytes and runny noses. Circulation 94: 607-609.
69. Roy M-L, Dumanine R, Brown AM (1996). HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94: 817-823.
70. Sanguinetti MC, Mitcheson JS (2005). Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 26: 119-124.
71. Sasaki H, Shimizu N, Suganami H, Yamamoto K (2005). QT PRODACT: inter-facility variability in electrocardiographic and hemodynamic parameters in conscious dogs and monkeys. J Pharmacol Sci 99: 513-522.
72. Schiefe RT, Cramer W (1996). Sedative and Cardiovascular Profile of Newer Antihistamines. Consult Pharm 10: 37-45.
73. Shah RR (2005). Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Safety 28: 1009-1028.
74. Shah RR (2008). If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed? Pharmacol Therap (in press). doi: 10.1016/j.pharmthera.2008.03.002.
75. Shah RR, Hondeghem LM(2005). Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2: 758-772.
76. Slack M, Kirchhoff C, Moller C, Winkler K, Netzer R (2006). Identification of novel Kv1.3 blockers using a fluorescent cell-based ion channel assay. J Biomol Screen 11: 57-64.
77. Sorota S, Zhang XS, Margulis M, Tucker K, Priestley T (2005). Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen. Assay Drug Dev Technol 3: 47-57.
78. Tashibu H, Miyazaki H, Aoki K, Akie Y, Yamamoto K (2005). QT PRODACT: in vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals. J Pharmacol Sci 99: 473-486.
79. Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, van Opstal J et al. (2004). Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 110: 2453-2459.
80. Tontodonati M, Fasdelli N, Moscardo E, Giarola A, Dorigatti R (2007). A canine model used to simultaneously assess potential neuro-behavioural and cardiovascular effects of candidate drugs. J Pharmacol Toxicol Methods 56: 265-275.
81. Toyoshima S, Kanno A, Kitayama T, Sekiya K, Nakai K, Haruna M et al. (2005). QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J Pharmacol Sci 99: 459-471.
82. US Food and Drug Administration (1997). S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals Federal Register. 62: 61515-61519.
83. US Food and Drug Administration (2001). Guidance for industry: safety pharmacology studies for human pharmaceuticals (S7A). http://www.fda.gov/cber/ gdlns/ichs7a071201.htm.
84. US Food and Drug Adminstration (2005a). Title 21, part 58 good laboratory practise for non clinical laboratories. 12: 301-303.
85. US Food and Drug Administration (2005b). Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (E14). http://www.fda.gov/cber/gdlns/iche14qtc.pdf.
86. Valentin JP, Hoffmann P, De Clerck F, Hammond TG, Hondeghem L (2004). Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J Pharmacol Toxicol Methods 49: 171-181.
87. Vargas HM, Bass AS, Breidenbach A, Feldman HS, Gintant GA, Harner A et al. (2008). Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods (in press) doi: 10.1016/j.vascn.2008.05.003.
88. Wang D, Patel C, Cui C, Yan G-X. (2008). Preclinical assessment of drug-induced proarrhythmias: role of the arterially perfused rabbit left ventricular wedge preparation. Pharmacology and Therapeutics (in press) doi:10.1016/j.pharmthera.2008.02.009.
89. Weerts EM, Fantegrossi WE, Goodwin AK (2007). The value of non-human primates in drug abuse research. Clin Exp Psychopharmacol 15: 309-327.
90. Weiss JN, Garfinkel A, Karagueuzian HS, Qu Z, Chen PS (1999). Chaos and the transition to ventricular fibrillation a new approach to antiarrhythmic drug evaluation. Circulation 99: 2819-2826.
91. Yamaguchi M, Shimizu M, Ino H, Terai H, Uchiyama K, Oe K et al. (2003). T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (London) 105: 671-676.
92. Yap YG, Camm AJ (1999). Arrhythmogenic mechanisms of non-sedating antihistamines. Clin Exp Allergy 29: 174-181.
93. Zheng W, Spencer RH, Kiss L (2004). High throughput assay technologies for ion channel drug discovery. Assay Drug Dev Technol 2: 543-552.